EPS for Radius Health, Inc. (RDUS) Expected At $-1.49

February 14, 2018 - By Marguerite Chambers

 EPS for Radius Health, Inc. (RDUS) Expected At $ 1.49
Investors sentiment decreased to 1.37 in 2017 Q3. Its down 0.05, from 1.42 in 2017Q2. It fall, as 27 investors sold Radius Health, Inc. shares while 25 reduced holdings. 22 funds opened positions while 49 raised stakes. 52.25 million shares or 10.87% more from 47.13 million shares in 2017Q2 were reported.
State Street Corp holds 0.01% or 2.50 million shares in its portfolio. Blackrock owns 3.00M shares. Parametric Portfolio Lc owns 7,727 shares or 0% of their US portfolio. Sei Investments, a Pennsylvania-based fund reported 76,407 shares. Franklin Res accumulated 432,600 shares. Sweden-based Rhenman And Prtn Asset Ab has invested 0.44% in Radius Health, Inc. (NASDAQ:RDUS). Proshare Advsr Ltd owns 28,004 shares. 5,587 are owned by Tudor Corporation Et Al. Temasek (Private) stated it has 19,344 shares or 0% of all its holdings. Oz L P has invested 0.02% of its portfolio in Radius Health, Inc. (NASDAQ:RDUS). Landscape Lc accumulated 0.08% or 20,519 shares. Pointstate Capital L P has 0.29% invested in Radius Health, Inc. (NASDAQ:RDUS) for 871,500 shares. Invesco Ltd owns 11,328 shares or 0% of their US portfolio. 10 are owned by Loring Wolcott & Coolidge Fiduciary Advisors Llp Ma. Evercore Wealth Limited Liability Corporation accumulated 6,435 shares or 0.01% of the stock.

Since August 16, 2017, it had 4 insider buys, and 0 selling transactions for $10.17 million activity.

Analysts expect Radius Health, Inc. (NASDAQ:RDUS) to report $-1.49 EPS on February, 22.They anticipate $0.27 EPS change or 22.13 % from last quarter’s $-1.22 EPS. After having $-1.31 EPS previously, Radius Health, Inc.’s analysts see 13.74 % EPS growth. The stock increased 3.87% or $1.41 during the last trading session, reaching $37.83. About 581,163 shares traded. Radius Health, Inc. (NASDAQ:RDUS) has risen 9.02% since February 14, 2017 and is uptrending. It has underperformed by 7.68% the S&P500.

Radius Health, Inc. (NASDAQ:RDUS) Ratings Coverage

Among 11 analysts covering Radius Health (NASDAQ:RDUS), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. Radius Health had 29 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Radius Health, Inc. (NASDAQ:RDUS) has “Hold” rating given on Monday, September 4 by Jefferies. The firm has “Buy” rating given on Friday, March 24 by H.C. Wainwright. On Wednesday, September 21 the stock rating was maintained by H.C. Wainwright with “Buy”. The company was reinitiated on Friday, May 6 by Cowen & Co. The stock has “Buy” rating by Canaccord Genuity on Thursday, September 24. Goldman Sachs initiated Radius Health, Inc. (NASDAQ:RDUS) on Wednesday, March 30 with “Neutral” rating. The company was maintained on Thursday, July 13 by Cantor Fitzgerald. As per Sunday, July 23, the company rating was maintained by Cantor Fitzgerald. The stock of Radius Health, Inc. (NASDAQ:RDUS) earned “Hold” rating by Citigroup on Wednesday, December 6. The stock of Radius Health, Inc. (NASDAQ:RDUS) earned “Overweight” rating by JP Morgan on Friday, October 2.

Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States. The company has market cap of $1.69 billion. The Company’s product candidates include Abaloparatide-SC, an injectable subcutaneous formulation of abaloparatide, which has completed Phase III clinical trial for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch for use as a short wear-time transdermal patch. It currently has negative earnings. The firm is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer.

More important recent Radius Health, Inc. (NASDAQ:RDUS) news were published by: Seekingalpha.com which released: “Radius Health: Updates To Thesis” on January 30, 2018, also Prnewswire.com published article titled: “This Morning’s Technical Outlook on Biotech Stocks — Portola Pharma, Protalix …”, Benzinga.com published: “Analyst: Radius Health Could Advance 50% With Osteoporosis Treatment, Breast …” on January 29, 2018. More interesting news about Radius Health, Inc. (NASDAQ:RDUS) was released by: Globenewswire.com and their article: “Radius Health to Present at Leerink Partners 7th Annual Global Healthcare …” with publication date: February 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: